TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CellaVision AB ( (SE:CEVI) ) has provided an update.
CellaVision AB’s third quarter of 2025 showed mixed regional performance with a slight decrease in net sales, impacted by currency effects and changes in the supply chain. Despite these challenges, the company remains optimistic about its long-term growth, driven by strong demand for its products, particularly in the US and APAC regions. Strategic advancements include the completion of European clinical trials for a new bone marrow application and the upcoming launch of upgraded software for hematology analyzers, reflecting CellaVision’s commitment to innovation and enhanced diagnostic solutions.
The most recent analyst rating on (SE:CEVI) stock is a Buy with a SEK199.00 price target. To see the full list of analyst forecasts on CellaVision AB stock, see the SE:CEVI Stock Forecast page.
More about CellaVision AB
CellaVision AB operates in the healthcare sector, specializing in digital morphology solutions and hematology analyzers. The company focuses on improving laboratory workflows and patient care through intelligent microscopy and strategic partnerships.
Average Trading Volume: 23,522
Technical Sentiment Signal: Sell
Current Market Cap: SEK4.23B
See more data about CEVI stock on TipRanks’ Stock Analysis page.